Web Analytics

3 Latest Announced Rounds

  • $67,000,000
    Series A
    Biotechnology Research
    Apr 2nd, 2025
  • $10,000,000
    Seed

    2 Investors

    Software Development
    Apr 2nd, 2025
  • $5,200,000
    Series A

    3 Investors

    Technology, Information and Internet
    Apr 2nd, 2025
$1,676.17M Raised in 53 Funding Rounds in the past 7 Days - View All

Funding Round Profile

ArsenalBio

start up
United States - South San Francisco , CA
  • 09/09/2022
  • Series B
  • $220,000,000

ArsenalBio is a privately held, programmable cell therapy company focused on the realization of solid tumor cell therapy to defeat cancer. Our discovery engine comprises precise CRISPR-enabled genome editing, integrated circuits incorporating logic gates for improved tumor targeting, and therapeutic enhancements enabling multiple pharmaceutical functions. With our programmable and computationally driven approach, we aim for enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. Our team is engineering living medicines to attack cancer’s inherent multi-faceted nature and bring dramatic improvements to the lives of patients.


Related People

Ken DrazanCo Founder

Ken Drazan United States - San Francisco Bay Area

N/A